Ping An Biomedical Co., Ltd.

6-K 1 ea0309492-6k_pingan.htm REPORT OF FOREIGN PRIVATE ISSUER

UNDER THE SECURITIES EXCHANGE ACT OF 1934

22/F, China United Plaza, 1002-1008, Tai Nan West Street,

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On October 22, 2026, Ping An Biomedical Co., Ltd. (the "Company") entered into a letter of intent with Future Biotechnology Group Co., Limited, for the planned acquisition (the "Planned Acquisition") of three tumor cell-related medical technology patents covering areas including oncology diagnosis and treatment, cell detection and bioengineering, and biomarker and DNA probe technologies, for a consideration ranging from US 2 million to US 2.5 million. The Planned Acquisition shall be subject to a final acquisition agreement to be subsequently prepared and executed by the parties.

On October 22, 2026, the Company issued a press release, a copy of which is filed as Exhibit 99.1 hereto, and incorporated herein by reference.

99.1 Press Release dated October 22, 2026